Read More
A dual-antigen vaccine under development by CK Life Sciences (0775) has shown positive effects in treating liver cancer during preclinical trials.
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
If the vaccine is successfully commercialized, it will probably be 50 percent cheaper than a global best-selling drug which costs around US$120,000 (HK$936,000) a year, estimates Melvin Toh Kean-meng, vice president and chief scientific officer of CKLS.
The investigational vaccine targets two antigens - Prame or peferentially expressed antigen in melanoma and PD-L1 - from cancer cells to activate immune responses.
It mainly aims to detect cancer cells in the early stage and deter cancer growth, helping prolong the survival of liver cancer patients. During preclinical experiments, mice were vaccinated four to five times at a two-week interval.
CKLS hopes to start clinical trials in the coming years and will improve the formula to treat liver cancer, the second most common cause of cancer deaths in Asia. It will also explore whether the vaccine can treat other types of cancers.
CKLS will introduce its findings at the Society for Immunotherapy of Cancer's 2023 annual meeting, sharing the data with global experts and investors.
In other news, CKLS vice president and chief executive Alan Abel Yu Ying-choi said China's tariffs on Australian wine have no impact on its vineyards in the country, as it only leases out the farmlands.













